Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 16/20 | 1.00 |
| ▸ | CNR1 | P21554 | 14/20 | 1.00 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 1.00 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 1.00 |
| ▸ | TRPA1 | O75762 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 1.00 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 1.00 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 1.00 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 1.00 |
| ▸ | TRPV5 | Q9NQA5 | 1/20 | 1.00 |
| ▸ | TRPV2 | Q9Y5S1 | 1/20 | 1.00 |
| ▸ | ABHD12 | Q8N2K0 | 3/20 | 0.86 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.86 |
| ▸ | FAAH | O00519 | 2/20 | 0.86 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.86 |
| ▸ | LDHA | P00338 | 1/20 | 0.86 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.86 |
| ▸ | GPR183 | P32249 | 1/20 | 0.86 |
| ▸ | DRD3 | P35462 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrocannabivarin SCHEMBL29904669 | 1.00 | CNR2 (1.00) | CNR2CNR1TRPM8GPR55TRPA1 | |
| Tetrahydrocannabivarin SCHEMBL29422123 | 1.00 | CNR2 (1.00) | CNR2CNR1TRPM8GPR55TRPA1 | |
| Tetrahydrocannabivarin SCHEMBL30017852 | 1.00 | CNR2 (1.00) | CNR2CNR1TRPM8GPR55TRPA1 | |
| Tetrahydrocannabivarin SCHEMBL31300003 | 1.00 | CNR2 (1.00) | CNR2CNR1TRPM8GPR55TRPA1 | |
| Tetrahydrocannabivarin SCHEMBL31544930 | 1.00 | CNR2 (1.00) | CNR2CNR1TRPM8GPR55TRPA1 | |
| Tetrahydrocannabivarin SCHEMBL18371743 | 1.00 | CNR2 (1.00) | CNR2CNR1TRPM8GPR55TRPA1 | |
| Tetrahydrocannabivarin SCHEMBL29350511 | 1.00 | CNR2 (1.00) | CNR2CNR1TRPM8GPR55TRPA1 | |
| Tetrahydrocannabivarin SCHEMBL245827 | 1.00 | CNR2 (1.00) | CNR2CNR1TRPM8GPR55TRPA1 | |
| Tetrahydrocannabivarin SCHEMBL21363566 | 1.00 | CNR2 (1.00) | CNR2CNR1TRPM8GPR55TRPA1 | |
| Tetrahydrocannabivarin SCHEMBL25731794 | 1.00 | CNR2 (1.00) | CNR2CNR1TRPM8GPR55TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 423 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| US-20230190670-A1 | COMPOSITIONS COMPRISING NOVEL CANNABINOID AND TERPENE PROFILES | Natural Extraction Systems, LLC (US) | 2023-06-22 | — | — | US | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021127559-A1 | COMPOSITIONS COMPRISING CANNABINOID ANIONS AND ANTI-NUCLEATING AGENTS | Natural Extraction Systems, LLC (US) | 2021-06-24 | — | — | WO | claimed |
| WO-2021113261-A1 | COMPOSITIONS COMPRISING NOVEL CANNABINOID AND TERPENE PROFILES | Natural Extraction Systems, LLC (US) | 2021-06-10 | — | — | WO | claimed |
| US-10807931-B2 | Synthesis of phytocannabinoids including a decarboxylation step | THE UNIVERSITY OF SYDNEY (AU) | 2020-10-20 | — | — | US | claimed |
| US-20200172459-A1 | SYNTHESIS OF PHYTOCANNABINOIDS INCLUDING A DECARBOXYLATION STEP | THE UNIVERSITY OF SYDNEY (AU) | 2020-06-04 | — | — | US | claimed |
| EP-3962296-B1 | CANNABINOID COMPOSITIONS AND METHODS OF USING | GREENWAY HERBAL PRODUCTS LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12582663-B2 | Compositions comprising decarboxylated cannabinoids | Natural Extraction Systems, LLC (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260077009-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | Neurotech International Ltd (AU) | 2026-03-19 | — | — | US | disclosed |
| US-20250380732-A1 | AEROSOLISABLE FORMULATION | NICOVENTURES TRADING LTD (GB) | 2025-12-18 | — | — | US | disclosed |
| US-20250368594-A1 | COMPOSITIONS AND METHODS TO SEPARATE CANNABINOIDS FROM IMPURITIES BY CRYSTALLIZATION | NATURAL EXTRACTION SYS LLC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20130059018-A1 | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | OTSUKA PHARMACEUTICAL CO., LIMITED (JP) | 2013-03-07 | — | — | US | disclosed |
| US-20130059018-A1 | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | OTSUKA PHARMACEUTICAL CO., LIMITED (JP) | 2013-03-07 | — | — | US | disclosed |
| WO-2011110866-A1 | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | GW PHARMA LIMITED (GB) | 2011-09-15 | — | — | WO | disclosed |
| US-20100204312-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100204312-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | CNR2 3068/4885CNR1 3464/4885TRPM8 1161/4885 |
| US-20200172459-A1 | SYNTHESIS OF PHYTOCANNABINOIDS INCLUDING A DECARBOXYLATION STEP | CNR2, CNR1, CCNB1 | CNR2 1/4885CNR1 2/4885TRPM8 2093/4885 |
| US-20130059018-A1 | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | CNR1, CNR2, LSS | CNR2 2/4885CNR1 1/4885TRPM8 2241/4885 |
| US-20260077009-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | CNR2, CNR1, SNCA | CNR2 1/4885CNR1 2/4885TRPM8 351/4885 |
| US-20100204312-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | CNR2, CNR1, JUP | CNR2 1/4885CNR1 2/4885TRPM8 2766/4885 |
| US-12582663-B2 | Compositions comprising decarboxylated cannabinoids | GGPS1, PGGT1B, CNR2 | CNR2 3/4885CNR1 8/4885TRPM8 2217/4885 |
| US-10807931-B2 | Synthesis of phytocannabinoids including a decarboxylation step | CNR2, CNR1, CCNB1 | CNR2 1/4885CNR1 2/4885TRPM8 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.